Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023
March 23, 2023 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that it plans to release financial results for the fourth quarter and full...
Eledon to Present Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation at the World Congress of Nephrology 2023
March 23, 2023 08:00 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the Company will present two posters at the upcoming International...
Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
February 08, 2023 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, Chief Executive Officer, will present at the...
Eledon Pharmaceuticals Provides Business and Pipeline Updates
January 09, 2023 08:31 ET
|
Eledon Pharmaceuticals, Inc.
Company plans to prioritize and focus resources on the advancement of tegoprubart in kidney transplantation Continued enrollment in open-label Phase 1b kidney transplant trial with initial data...
C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System
December 21, 2022 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path) announced on December 20, 2022, that its Transplant Therapeutic Consortium (TTC) received a qualification opinion...
Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results
November 14, 2022 16:01 ET
|
Eledon Pharmaceuticals, Inc.
Received FDA clearance of IND application to evaluate tegoprubart in a Phase 2 trial for the prevention of rejection in patients receiving a kidney transplant Dosed initial two patients in ex-U.S....
Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
November 03, 2022 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that it plans to release financial results for the third quarter...
Eledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS
October 24, 2022 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that the Company will present two posters at the upcoming American Society...
Eledon Pharmaceuticals to Participate in Two Upcoming Conferences
October 03, 2022 08:00 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that senior management will participate in two upcoming conferences: A...
Eledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
September 22, 2022 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that David-Alexandre C. Gros, Chief Executive Officer, will participate in...